Iron-Deficiency Anemia (IDA)

Definition and Epidemiology

• Systemic nutritional disorder characterized by depletion of total body iron content.
• Impairs heme synthesis, limits erythropoiesis, and induces tissue hypoxia.
• Most prevalent nutritional deficiency globally, affecting over 2 billion individuals.
• Pediatric incidence demonstrates bimodal distribution.
• First peak: 6 months to 3 years. Attributed to rapid somatic growth outstripping dietary intake.
• Second peak: 11 to 17 years. Attributed to pubertal growth spurt and onset of menstrual blood loss in females.

Etiopathogenesis

Nutritional Deficiency

• Inadequate intake constitutes the most common etiology.
• Breastfeeding beyond 6 months without supplemental dietary or medicinal iron.
• Excessive whole cow milk consumption (>24 oz/day).
• Iron bioavailability in cow milk severely limited (~10%) compared to breast milk (20–80%).
• High calcium concentration in bovine milk competitively inhibits iron absorption.
• Vegan or strict vegetarian diets lacking appropriate fortification.

Increased Physiologic Demand

• Prematurity, low birth weight, multiple gestation. Neonatal iron stores proportional to body weight; rapidly depleted by 3-4 months in premature infants compared to 6 months in term infants.
• Rapid somatic growth phases (infancy, adolescence, pregnancy).
• Chronic hypoxia leading to polycythemia (cyanotic congenital heart disease).

Blood Loss (Overt or Occult)

• Perinatal: Fetomaternal hemorrhage, twin-to-twin transfusion, retroplacental bleeding, iatrogenic phlebotomy losses.
• Gastrointestinal: Hypersensitivity to cow milk protein inducing exudative enteropathy and chronic microhemorrhage.
• Anatomic GI lesions: Peptic ulcer disease, Meckel diverticulum, inflammatory bowel disease, polyposis syndromes, hereditary hemorrhagic telangiectasia.
• Parasitic infestation: Endemic areas. Hookworm (Necator americanus, Ancylostoma duodenale), whipworm (Trichuris trichiura), schistosomiasis.
• Genitourinary/Pulmonary: Menorrhagia, abnormal uterine bleeding, recurrent epistaxis, idiopathic pulmonary hemosiderosis, Goodpasture syndrome, paroxysmal nocturnal hemoglobinuria.

Impaired Absorption and Transport

• Gastrointestinal mucosal disease: Celiac disease, tropical sprue, inflammatory bowel disease.
• Gastric alterations: Helicobacter pylori gastritis, antacid therapy, elevated gastric pH, gastric bypass, intestinal resection.
• Iron-Refractory Iron-Deficiency Anemia (IRIDA): Rare autosomal recessive disorder. Pathogenic variant in TMPRSS6 gene (encodes matriptase-2). Abrogates hepcidin inhibition. Elevated hepcidin perpetually blocks intestinal iron absorption and macrophage iron release.
• Genetic transport defects: Atransferrinemia (mutated TF gene), aceruloplasminemia (mutated CP gene).

Pathophysiology: Sequential Stages of Iron Depletion

Stage 1: Iron Depletion

• Depletion of reticuloendothelial tissue iron stores.
• Serum ferritin concentration drops.
• Hemoglobin, hematocrit, and serum iron levels remain strictly normal.

Stage 2: Iron-Deficient Erythropoiesis

• Macrophage iron stores fully exhausted.
• Serum iron declines. Total iron-binding capacity (TIBC) increases.
• Erythropoiesis limited by lack of bioavailable iron.
• Soluble transferrin receptor (sTfR) levels rise. Reticulocyte hemoglobin content (Ret-He) falls.
• Hematocrit remains normal without overt anemia.

Stage 3: Iron-Deficiency Anemia

• Iron deficiency prolonged. Large proportion of circulating erythrocytes produced under iron-limiting conditions.
• Hemoglobin concentration drops below age-adjusted normal range.
• Erythrocytes exhibit microcytosis and hypochromia.
• Red cell distribution width (RDW) increases. Free erythrocyte protoporphyrin (FEP) elevates markedly.

Clinical Manifestations

Hematologic and Systemic

• Insidious onset. Mild stages frequently asymptomatic.
• Early symptoms: Irritability, anorexia, lethargy, easy fatigability, weakness, tachycardia.
• Severe, persistent deficiency: Congestive heart failure, hepatosplenomegaly, dyspnea, flow murmurs.

Non-Hematologic Tissue Effects

• Gastrointestinal: Pica (compulsive craving for sand, dirt, clay, ice). Rapidly reverses with iron therapy prior to hematologic correction.
• Mucocutaneous: Angular stomatitis, atrophic glossitis (smooth, shiny, painful tongue).
• Esophageal: Dysphagia secondary to esophageal webs (Kelly-Paterson syndrome).
• Neurologic: Restless leg syndrome (discomfort relieved by movement; reflects CNS tissue iron deficiency). Apathy, impaired learning, cognitive deficits.
• Integumentary: Koilonychia (spoon-shaped nails), platynychia, marked pallor of palmar creases and conjunctivae.
• Immunologic: Impaired leukocyte transformation, decreased myeloperoxidase activity, heightened susceptibility to respiratory infections.

Diagnostic Evaluation

Primary Blood Indices

• Hemoglobin/Hematocrit: Reduced below age and sex-matched normative limits.
• Red Cell Indices: Mean Corpuscular Volume (MCV), Mean Corpuscular Hemoglobin (MCH), and Mean Corpuscular Hemoglobin Concentration (MCHC) significantly reduced.
• Red Cell Distribution Width (RDW): Elevated (>14.5%). Indicates marked anisocytosis. Differentiates from thalassemia trait where RDW remains normal (<13%).
• Reticulocyte Count: Relative percentage may appear elevated, but absolute or corrected reticulocyte Index is low or normal (<1.5%), reflecting hypoproliferative marrow response.
• Platelet Count: Variable. Reactive thrombocytosis common due to erythropoietin cross-reactivity. Severe IDA may present with thrombocytopenia.

Peripheral Blood Smear

• Erythrocytes exhibit hypochromia (central pallor exceeding 1/3 of cell diameter) and microcytosis (cells smaller than lymphocyte nucleus).
• Marked anisocytosis and poikilocytosis.
• Presence of teardrop cells, ovalocytes, elliptocytes, and occasional target cells.

Biochemical Iron Profile

• Serum Ferritin: <15 ng/mL. Highly specific and sensitive indicator of depleted body stores. Acute-phase reactant properties may falsely elevate levels during concurrent infection, inflammation, or malignancy.
• Serum Iron: Markedly reduced.
• Total Iron-Binding Capacity (TIBC): Increased.
• Transferrin Saturation: Reduced to <16% (Normal: 25-50%).

Advanced Diagnostic Markers

• Soluble Transferrin Receptor (sTfR): Elevated. Superior marker in complex cases as it remains unaffected by systemic inflammation.
• sTfR/log ferritin ratio: Highest diagnostic sensitivity and specificity. Ratio >2.9 confirms IDA, distinguishing it from anemia of chronic disease.
• Free Erythrocyte Protoporphyrin (FEP): Elevated. Reflects accumulation of protoporphyrin unable to bind absent iron for ultimate heme synthesis.
• Reticulocyte Hemoglobin Content (Ret-He): Reduced. Highly sensitive early indicator of iron-deficient erythropoiesis. First parameter to correct upon treatment initiation.
• Zinc Protoporphyrin/Heme Ratio: Increased. Zinc substitutes for iron within protoporphyrin IX ring during deficiency states.

Differential Diagnosis of Microcytic Anemias

Note: Diagnosis of beta-thalassemia trait via elevated HbA2 may be masked by concomitant IDA. Definitive hemoglobin electrophoresis should be delayed until iron stores are repleted.

Management Principles

Etiologic Correction and Dietary Counseling

• Address primary underlying etiology universally. Refer for gastroenterology endoscopy if occult bleeding suspected in non-menstruating populations.
• Exclusively breastfed infants: Initiate iron supplementation (1 mg/kg/day) at 4 months of age. Continue until adequate solid food intake.
• Premature infants: Initiate prophylactic iron (2 mg/kg/day) by 2 weeks of age.
• Limit cow milk consumption: Strictly avoid in first year of life. Restrict to <24 oz/day in toddlers to prevent occult enteropathy.
• Promote iron-rich dietary transition: Fortified cereals, meat, fish, and poultry.
• Dietary modifiers: Ascorbic acid (vitamin C) enhances enteral non-heme iron absorption. Discourage concomitant intake of tea, phytates, and phosphates.

Oral Iron Therapy

• First-line definitive management modality.
• Preparation: Ferrous sulfate (20% elemental iron) most economical and efficacious. Ferric compounds demonstrate inferior absorption.
• Dosage: 3 to 6 mg/kg/day of elemental iron.
• Administration: Maximize absorption by administering on empty stomach or between meals. Every-other-day dosing may improve GI tolerance and absorption efficiency in selected patients.
• Duration: Continue therapy for 4 to 6 months following complete hemoglobin normalization to replenish reticuloendothelial iron stores.
• Adverse Effects: Epigastric discomfort, nausea, vomiting, constipation, diarrhea, metallic taste, and harmless dark stools.

Monitoring Therapeutic Response

• Bone marrow megaloblastosis reverses within days, but not applicable for isolated IDA. Reticulocyte crisis observed at 5 to 10 days post-initiation.
• Hemoglobin concentration rises 0.25 to 0.4 g/dL/day initially. Target minimum increase of 1 g/dL at 1 month of therapy.
• Failure to respond mandates reassessment: Evaluate compliance, inadequate dose, persistent occult hemorrhage, concurrent malabsorption (celiac disease), concurrent inflammation, incorrect diagnosis (thalassemia trait), or IRIDA.

Parenteral Iron Therapy

• Indications limited to specific clinical scenarios: Severe GI intolerance, complete non-adherence to oral regimens, malabsorption syndromes (celiac disease, inflammatory bowel disease, prior gastrectomy), ongoing rapid hemorrhage exceeding enteral absorptive capacity, and congenital IRIDA.
• Concomitant use indicated with recombinant erythropoietin therapy (renal dialysis, oncology patients) to guarantee steady substrate supply.
• Formulations: Iron sucrose, ferric carboxymaltose, iron dextran. Intravenous administration mandatory; intramuscular injection strictly contraindicated due to severe pain, tissue staining, and erratic absorption.
• Dosage Calculation (Ganzoni Formula): Total cumulative dose (mg) = [Target Hb - Actual Hb] × Weight (kg) × 2.4 + [15 × Weight (kg)]. Test dose required for specific formulations like high-molecular-weight iron dextran.

Blood Transfusion

• Strictly contraindicated for routine correction of IDA. Reserved exclusively for acute emergencies.
• Indications: Severe, life-threatening anemia (Hb <4 g/dL), overt signs of congestive heart failure, imminent cardiovascular collapse, rapid uncontrolled hemorrhage, or urgent requirement for general anesthesia/surgery.
• Administration: Packed red blood cells. Slow continuous infusion rate (2 to 3 mL/kg) under stringent cardiovascular monitoring to prevent fatal volume overload.
• Partial exchange transfusion may be required to rapidly increase oxygen-carrying capacity without precipitating acute cardiac decompensation. Concomitant diuretic therapy frequently indicated.